These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18951493)

  • 61. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection.
    Aguirre K; Miller S
    Glia; 2002 Aug; 39(2):184-8. PubMed ID: 12112369
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regions.
    Egeland MT; Tarczyluk-Wells MM; Asmar MM; Adintori EG; Lawrence R; Snella EM; Jens JK; Crawford BE; Wait JCM; McCullagh E; Pinkstaff J; Cooper JD; Ellinwood NM
    Sci Rep; 2020 Nov; 10(1):20365. PubMed ID: 33230178
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serum MIP-1 alpha level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice.
    Di Natale P; Di Domenico C; Di Napoli D
    J Inherit Metab Dis; 2010 Apr; 33(2):159-65. PubMed ID: 20162365
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Murine cellular model of mucopolysaccharidosis, type IIIB (MPS IIIB) - A preliminary study with particular emphasis on the non-oxidative l-cysteine metabolism.
    Kaczor-Kamińska M; Stalińska K; Kamiński K; Pisarek A; Maziarz U; Feldman A; Wróbel M
    Biochimie; 2020 Jul; 174():84-94. PubMed ID: 32335228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
    Gilkes JA; Bloom MD; Heldermon CD
    Gene Ther; 2016 Mar; 23(3):263-71. PubMed ID: 26674264
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H
    Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.
    Roberts AL; Thomas BJ; Wilkinson AS; Fletcher JM; Byers S
    Pediatr Res; 2006 Sep; 60(3):309-14. PubMed ID: 16857766
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
    Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
    J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
    Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
    Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome.
    Gougeon ML; Poirier-Beaudouin B; Ausseil J; Zérah M; Artaud C; Heard JM; Deiva K; Tardieu M
    Front Immunol; 2021; 12():655478. PubMed ID: 34040605
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Muenzer J; Fu H
    Gene Ther; 2009 Nov; 16(11):1340-52. PubMed ID: 19587708
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular defects identified by whole exome sequencing in a child with atypical mucopolysaccharidosis IIIB.
    Zeng Q; Fan Y; Wang L; Huang Z; Gu X; Yu Y
    J Pediatr Endocrinol Metab; 2017 Apr; 30(4):463-469. PubMed ID: 28306536
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Peripheral nervous system neuropathology and progressive sensory impairments in a mouse model of Mucopolysaccharidosis IIIB.
    Fu H; Bartz JD; Stephens RL; McCarty DM
    PLoS One; 2012; 7(9):e45992. PubMed ID: 23049915
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
    Mader KM; Beard H; King BM; Hopwood JJ
    Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B.
    Trudel S; Trécherel E; Gomila C; Peltier M; Aubignat M; Gubler B; Morlière P; Heard JM; Ausseil J
    J Neurosci Res; 2015 Mar; 93(3):424-32. PubMed ID: 25332157
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
    Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
    J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
    Fu H; Dirosario J; Killedar S; Zaraspe K; McCarty DM
    Mol Ther; 2011 Jun; 19(6):1025-33. PubMed ID: 21386820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.